4 out of 5 women will have Human papillomavirus (HPV) at one point in their lives5, and if left untreated causes cervical cancer.6 In order to make progress towards eliminating cervical cancer, we must address and overcome current obstacles to screening.
Limited access, past trauma and anxiety are some barriers keeping women from getting screened. Self-collection* offers a more private and accessible option that can increase screening rates.
Choosing a test with extended genotyping can meet the needs of both vaccinated and unvaccinated patients by stratifying high and low risk HPV types, helping enable precise care decisions.
Using end-to-end and fully automated workflows, including integrated pre-analytics, improves accuracy, boosts operational efficiency and frees labs to focus on value-driven tasks.
Together, we can save more lives by vaccinating, screening and treating HPV early. BD is committed to supporting the World Health Organization’s mission of eliminating cervical cancer12 by setting the highest standards for testing.
As a single source, our advanced molecular and cytology testing solutions offer flexibility to accommodate preferred testing approaches from screening to triage.
We’re making it easier for women to access the most comprehensive results and understand their risk for cervical cancer through an accessible, private self-collection option.
Our solutions deliver the most advanced clinically-validated insights that empower precise patient care and fewer missed cases of cervical cancer.
Alleviate growing demands on labs with truly integrated, high-throughput molecular platforms that enable end-to-end, walkaway automation.
Position your lab at the forefront of progress
The BD COR™ System offers true end-to-end automation, including integrated specimen pre-analytics, so labs can expand access to high-performance tests and drive efficiency.
Get the most accurate liquid-based cytology test
BD SurePath™ Liquid-based Pap test enables higher cervical disease detection with a lower UNSAT rate, leading to fewer patient recalls and missed cases of cervical cancer.2
*Self-collected vaginal specimens, obtained in a healthcare setting, can be tested as an alternative specimen type when cervical sampling is either contraindicated or cervical samples otherwise cannot be obtained.
†The BD Onclarity™ HPV Assay is the only FDA-approved HPV test which provides the capability for individually genotyping six high-risk types and three genotype groups.
BD, the BD logo, COR, Surepath and Onclarity, are trademarks of Becton, Dickinson and Company or its affiliates. All other trademarks are the property of their respective owners. 2025 BD. All rights reserved.
